Literature DB >> 35068803

Versatility of Anabolic Androgenic Steroid-Induced Hepatotoxicity.

Vaibhav Patil1, Dinesh Jothimani1, Kavya Harika1, Abdul Rahman Hakeem1, Deepti Sachan2, Mukul Vij3, Mohamed Rela1.   

Abstract

The modified derivatives of testosterone, termed as androgenic steroids are indicated in the management of hypogonadism, visceral obesity and metabolic disorders. Anabolic androgenic steroids (AASs) however are surreptitiously used by athletes and body builders for cosmetic purpose owing to their anabolic effects on muscle mass and strength. The unsurveilled use of AASs subjects these users to various side effects involving multiple systems such as the endocrine, genitourinary, hepatobiliary, central nervous, musculoskeletal and psychosocial system. The liver is a hormone-sensitive organ owing to abundance of androgen receptors and is vulnerable to a wide array of hepatotoxicity ranging from asymptomatic liver enzyme elevation to life-threatening subacute liver failure. The type of drug-induced liver injury (DILI) due to AASs can be hepatocellular injury, cholestasis, fatty liver disease, chronic vascular injury and neoplastic disease. Herein, we report three cases of AAS-related DILI associated with AAS abuse.
© 2021 Indian National Association for Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  AAS, anabolic androgenic steroid; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AR, androgen receptor; AST, aspartate aminotransferase; CT, computed tomography; DILI; DILI, drug-induced liver injury; GGT, gamma-glutamyl transferase; HA, hepatocellular adenoma; HCC, hepatocellular carcinoma; HE, hepatic encephalopathy; HUMP, hepatocellular neoplasm of uncertain malignant potential; LDLT, living donor liver transplantation; LFT, liver function test; RUCAM, Roussel Uclaf Causality Assessment Method; SALF, subacute liver failure; TACE, transarterial chemoembolization; TPE, therapeutic plasma exchange; anabolic steroids; cholestasis; hepatocellular neoplasm; peliosis hepatis; steatosis

Year:  2021        PMID: 35068803      PMCID: PMC8766528          DOI: 10.1016/j.jceh.2021.03.003

Source DB:  PubMed          Journal:  J Clin Exp Hepatol        ISSN: 0973-6883


  13 in total

1.  Distinct phenotype of hepatotoxicity associated with illicit use of anabolic androgenic steroids.

Authors:  M Robles-Diaz; A Gonzalez-Jimenez; I Medina-Caliz; C Stephens; M García-Cortes; B García-Muñoz; A Ortega-Alonso; E Blanco-Reina; R Gonzalez-Grande; M Jimenez-Perez; P Rendón; J M Navarro; P Gines; M Prieto; M Garcia-Eliz; F Bessone; J R Brahm; R Paraná; M I Lucena; R J Andrade
Journal:  Aliment Pharmacol Ther       Date:  2014-11-13       Impact factor: 8.171

2.  Severe and protracted cholestasis in 44 young men taking bodybuilding supplements: assessment of genetic, clinical and chemical risk factors.

Authors:  Andrew Stolz; Victor Navarro; Paul H Hayashi; Robert J Fontana; Huiman X Barnhart; Jiezhun Gu; Naga P Chalasani; Maricruz M Vega; Herbert L Bonkovsky; Leonard B Seeff; Jose Serrano; Bharathi Avula; Ikhlas A Khan; Elizabeth T Cirulli; David E Kleiner; Jay H Hoofnagle
Journal:  Aliment Pharmacol Ther       Date:  2019-04-01       Impact factor: 8.171

3.  Hepatology: hepatocellular carcinoma in a young man secondary to androgenic anabolic steroid abuse.

Authors:  T Kesler; R S Sandhu; S Krishnamoorthy
Journal:  J Gastroenterol Hepatol       Date:  2014-11       Impact factor: 4.029

Review 4.  Anabolic Steroid Effect on the Liver.

Authors:  Mark W Niedfeldt
Journal:  Curr Sports Med Rep       Date:  2018-03       Impact factor: 1.733

5.  Hepatocellular Neoplasms Arising in Association With Androgen Use.

Authors:  Sounak Gupta; Bita V Naini; Richard Munoz; Rondell P Graham; Benjamin R Kipp; Michael S Torbenson; Taofic Mounajjed
Journal:  Am J Surg Pathol       Date:  2016-04       Impact factor: 6.394

Review 6.  Hepatotoxicity associated with illicit use of anabolic androgenic steroids in doping.

Authors:  R Solimini; M C Rotolo; L Mastrobattista; C Mortali; A Minutillo; S Pichini; R Pacifici; I Palmi
Journal:  Eur Rev Med Pharmacol Sci       Date:  2017-03       Impact factor: 3.507

7.  Peliosis hepatis following treatment with androgen-steroids in patients with bone marrow failure syndromes.

Authors:  P Tsirigotis; T Sella; M Y Shapira; M Bitan; A Bloom; D Kiselgoff; M Levin; D Libster; A Abdul Hai; B Gesundheit; R Or; S Slavin; I Resnick
Journal:  Haematologica       Date:  2007-11       Impact factor: 9.941

8.  Treatment with plasma exchange may serve benefical effect in patients with severe hyperbilirubinemia: a single center experience.

Authors:  Muzaffer Keklik; Serdar Sivgin; Leylagul Kaynar; Cigdem Pala; Musa Solmaz; Mustafa Cetin; Bulent Eser; Ali Unal
Journal:  Transfus Apher Sci       Date:  2013-04-16       Impact factor: 1.764

9.  Testosterone-receptor positive hepatocellular carcinoma in a 29-year old bodybuilder with a history of anabolic androgenic steroid abuse: a case report.

Authors:  Philipp Solbach; Andrej Potthoff; Hans-Jürgen Raatschen; Bisharah Soudah; Ulrich Lehmann; Andrea Schneider; Michael J Gebel; Michael P Manns; Arndt Vogel
Journal:  BMC Gastroenterol       Date:  2015-05-20       Impact factor: 3.067

10.  Androgenic anabolic steroid-induced liver injury: two case reports assessed for causality by the updated Roussel Uclaf Causality Assessment Method (RUCAM) score and a comprehensive review of the literature.

Authors:  Robin Daniel Abeles; Matthew Foxton; Shahid Khan; Robert Goldin; Belinda Smith; Mark R Thursz; Suman Verma
Journal:  BMJ Open Gastroenterol       Date:  2020-11
View more
  1 in total

Review 1.  Anabolic androgenic steroid-induced liver injury: An update.

Authors:  Ana Petrovic; Sonja Vukadin; Renata Sikora; Kristina Bojanic; Robert Smolic; Davor Plavec; George Y Wu; Martina Smolic
Journal:  World J Gastroenterol       Date:  2022-07-14       Impact factor: 5.374

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.